SHBG Calculator- Free Sex Hormone Binding Globulin and Free Androgen Index Tool

About This SHBG and Free Testosterone Calculator

This SHBG calculator is designed for anyone who has received sex hormone binding globulin blood test results and wants to understand what their SHBG level means in the context of overall hormone bioavailability. It computes the Free Androgen Index (FAI), calculates free testosterone using the clinically validated Vermeulen equation, estimates bioavailable testosterone, and classifies all values against sex-specific reference ranges. The tool serves clinicians interpreting hormone panels and individuals seeking to understand their androgen status.

The calculator employs the Vermeulen equation published in the Journal of Clinical Endocrinology and Metabolism (1999), which uses the known association constants for testosterone binding to SHBG (Kt = 10^9 L/mol) and albumin (Ka = 3.6 x 10^4 L/mol) to solve a quadratic equation for free testosterone concentration. The Free Androgen Index is calculated as (Total Testosterone / SHBG) x 100, following the standard formula endorsed by the Endocrine Society for screening androgen excess in women. Reference ranges are based on published clinical laboratory values from major reference laboratories.

The visualization combines four display approaches for comprehensive analysis: traffic light status cards provide instant visual assessment of each parameter, color-coded reference range bars with sliding markers show exactly where values fall on the clinical spectrum, a lab panel dashboard mimics clinical laboratory reports with N/L/H flags for familiar interpretation, and a clinical interpretation section generates context-specific recommendations based on the pattern of results. All calculations update in real-time as inputs change.

SHBG Calculator: Complete Guide to Sex Hormone Binding Globulin, Free Androgen Index, and Hormone Bioavailability

Sex Hormone Binding Globulin (SHBG) is one of the most clinically significant yet underappreciated biomarkers in endocrinology. This glycoprotein, produced primarily by the liver, acts as the body’s hormone traffic controller, determining how much testosterone, dihydrotestosterone (DHT), and estradiol remain biologically available to tissues. Understanding SHBG levels is essential for accurately interpreting total hormone measurements, diagnosing conditions such as polycystic ovary syndrome (PCOS), hypogonadism, and metabolic syndrome, and guiding treatment decisions for hormone replacement therapy.

The SHBG calculator on this page provides a comprehensive analysis of your SHBG levels in context with total testosterone, allowing you to compute the Free Androgen Index (FAI), estimated free testosterone, and bioavailable testosterone using the clinically validated Vermeulen equation. Whether you are a clinician interpreting lab results or an individual seeking to understand your hormonal status, this tool delivers the derived values and clinical classifications needed for informed decision-making.

What Is Sex Hormone Binding Globulin (SHBG)?

Sex Hormone Binding Globulin is a homodimeric plasma glycoprotein with a molecular weight of approximately 90-100 kilodaltons (kDa). The gene encoding SHBG is located on chromosome 17p13.1. Each SHBG molecule contains two identical subunits, and each subunit has a single steroid-binding site with high affinity for certain sex steroids. SHBG is synthesized predominantly in the liver, although smaller amounts are produced in the brain, uterus, testes, and placenta.

SHBG binds to sex hormones with varying affinities. It has the highest binding affinity for dihydrotestosterone (DHT), followed by testosterone, and then estradiol. Weaker androgens such as dehydroepiandrosterone (DHEA) and androstenedione bind poorly to SHBG. This differential binding affinity means that SHBG has a disproportionately large effect on the bioavailability of androgens compared to estrogens.

In the bloodstream, testosterone exists in three distinct pools. Approximately 1-3% circulates as free (unbound) testosterone, roughly 20-40% is loosely bound to albumin, and the remaining 50-70% is tightly bound to SHBG. Only the free and albumin-bound fractions are considered biologically active, because the weak albumin-testosterone bond can easily dissociate at the tissue level. The SHBG-bound fraction, by contrast, is considered biologically inactive due to the high binding affinity that prevents testosterone from accessing androgen receptors in target tissues.

Why SHBG Matters: Clinical Significance

SHBG is far more than a simple transport protein. It functions as a critical regulator of sex hormone bioavailability and serves as a metabolic barometer reflecting the interplay between the endocrine system, liver function, and metabolic health. Two individuals with identical total testosterone levels can have vastly different free testosterone concentrations depending on their SHBG levels, leading to completely different clinical presentations.

In men, elevated SHBG can create a state of functional androgen deficiency despite apparently normal total testosterone levels. This scenario is particularly common in aging men, where SHBG rises progressively while total testosterone declines modestly, resulting in a disproportionate decrease in bioavailable testosterone. Conversely, low SHBG in men may mask true testosterone deficiency by keeping free testosterone levels within the normal range even when total production is declining.

In women, SHBG plays an especially pivotal role because the ratio of SHBG to testosterone is much higher (typically 10:1 to 100:1), meaning that small changes in SHBG concentration can dramatically alter free androgen levels. Low SHBG in women is strongly associated with polycystic ovary syndrome (PCOS), insulin resistance, and hyperandrogenism. The Endocrine Society has noted that the Free Androgen Index (FAI), calculated from total testosterone and SHBG, correlates well with free testosterone in women, making it a clinically useful screening tool for androgen excess.

Factors That Influence SHBG Levels

Understanding what raises and lowers SHBG is essential for interpreting test results in their proper clinical context. SHBG production by the liver is regulated by a complex interplay of hormonal, metabolic, and genetic factors.

Factors that increase SHBG levels include estrogens (including oral contraceptive pills and hormone replacement therapy), hyperthyroidism, liver disease (particularly cirrhosis), aging in men, pregnancy, anticonvulsant medications (such as phenytoin and carbamazepine), low body weight or caloric restriction, and HIV infection. Estrogen is one of the most potent stimulators of hepatic SHBG production, which explains why women on oral contraceptives often have markedly elevated SHBG levels.

Factors that decrease SHBG levels include androgens (both endogenous and exogenous), insulin and insulin resistance, obesity (particularly visceral adiposity), hypothyroidism, glucocorticoids, growth hormone excess (acromegaly), progestins, nephrotic syndrome, and polycystic ovary syndrome. Insulin appears to directly suppress hepatic SHBG production, which explains the strong inverse correlation between SHBG and insulin resistance observed across numerous population studies.

SHBG Reference Ranges by Age and Sex

SHBG reference ranges vary between laboratories depending on the assay platform used, but the following ranges represent widely accepted clinical values. It is important to note that SHBG levels change significantly across the lifespan and differ substantially between males and females.

For adult males, the general reference range is approximately 10-57 nmol/L, with some laboratories reporting ranges up to 80 nmol/L for older men. In adult non-pregnant females, the reference range is approximately 18-144 nmol/L. During pregnancy, SHBG levels can rise dramatically due to increased estrogen production, sometimes reaching 200-300 nmol/L or higher.

In men, SHBG levels tend to increase with age. Studies have shown that median SHBG rises from approximately 20-25 nmol/L in men aged 20-30 years to approximately 35-45 nmol/L in men over 70 years. This age-related increase, combined with declining testosterone production, results in a progressive decrease in bioavailable testosterone that may contribute to symptoms of late-onset hypogonadism. In women, the age-related pattern is more complex, with a general decrease during the reproductive years followed by an increase after menopause, creating a U-shaped curve across the lifespan.

The Free Androgen Index (FAI): Calculation and Clinical Use

The Free Androgen Index is a mathematical ratio that estimates the proportion of testosterone that is biologically available. It was originally proposed as a screening tool for assessing circulating testosterone availability in women with hirsutism and has since become widely used in clinical practice, particularly for evaluating suspected androgen excess in women.

Normal FAI values differ significantly between sexes. In adult men, typical healthy FAI values range from approximately 30 to 150. Values below 30 in men may indicate functional testosterone deficiency and have been associated with symptoms including fatigue, decreased libido, erectile dysfunction, and reduced bone mineral density. In women, normal FAI values are substantially lower, typically ranging from 0.3 to 5.6 in premenopausal women and 0.2 to 3.6 in postmenopausal women. In women, elevated FAI values above 5-7 are suggestive of androgen excess and may support a diagnosis of PCOS when combined with clinical features.

It is important to understand the limitations of the FAI. The Endocrine Society has specifically recommended against using FAI as a surrogate for free testosterone in men, because in males, testosterone production is regulated by gonadotropin feedback. Changes in SHBG that alter free testosterone concentrations are compensated by autoregulation of testosterone production. However, in women, where much circulating testosterone derives from peripheral conversion of adrenal precursors (not subject to feedback control), the FAI correlates well with directly measured free testosterone.

Calculating Free and Bioavailable Testosterone: The Vermeulen Equation

The Vermeulen equation, published in 1999 by Alex Vermeulen, Lieve Verdonck, and Jean M. Kaufman at the University Hospital of Ghent, Belgium, provides a mathematically rigorous method for calculating free testosterone from measured total testosterone, SHBG, and albumin concentrations. This equation is based on mass action principles and the known association constants for testosterone binding to both SHBG and albumin.

The Vermeulen method has been validated against the gold standard equilibrium dialysis method and has been shown to produce nearly identical results under most clinical conditions, with the notable exception of pregnancy (where estradiol occupies a substantial fraction of SHBG binding sites, causing the calculation to underestimate free testosterone). The calculated free testosterone value from the Vermeulen equation has been endorsed by multiple endocrine societies as a reliable clinical tool and is considered superior to the Free Androgen Index for estimating bioavailable testosterone in men.

Bioavailable testosterone is defined as the sum of free testosterone plus albumin-bound testosterone. Because the albumin-testosterone bond is weak and readily dissociable at the tissue level, albumin-bound testosterone is considered biologically available. Bioavailable testosterone can be calculated from the Vermeulen-derived free testosterone value using the formula: Bioavailable T = Free T x (1 + Ka x Albumin), where Ka is the association constant for albumin-testosterone binding. When serum albumin is assumed at 4.3 g/dL (43 g/L), the constant factor becomes approximately 22.43.

Unit Conversions for Global Users

Testosterone and SHBG can be reported in different units depending on the laboratory and region. Accurate calculations require that inputs are in the correct units.

For testosterone, the most common units are nmol/L (nanomoles per liter, used in most countries) and ng/dL (nanograms per deciliter, commonly used in the United States). The conversion factor is: 1 nmol/L = 28.842 ng/dL, or equivalently, ng/dL x 0.03467 = nmol/L. SHBG is almost universally reported in nmol/L. Albumin is typically reported in g/L in most countries and g/dL in the United States, with the conversion: 1 g/dL = 10 g/L.

Clinical Conditions Associated with Abnormal SHBG

Abnormal SHBG levels can both result from and contribute to a wide range of clinical conditions. Understanding these associations is essential for proper interpretation of SHBG results and for identifying underlying pathology.

High SHBG conditions include hyperthyroidism, where thyroid hormones directly stimulate hepatic SHBG production; hepatic cirrhosis, where impaired estrogen metabolism leads to relative estrogen excess and increased SHBG synthesis; aging in men, where SHBG rises approximately 1-2% per year after age 40; oral estrogen therapy, including contraceptive pills and hormone replacement therapy; pregnancy, where SHBG can increase two to three-fold; anorexia nervosa and severe caloric restriction; and certain genetic polymorphisms in the SHBG gene that result in constitutively elevated production.

Low SHBG conditions include polycystic ovary syndrome (PCOS), one of the most common endocrine disorders in reproductive-age women, where insulin resistance drives down SHBG production; obesity, particularly central or visceral adiposity; type 2 diabetes and metabolic syndrome; hypothyroidism; Cushing syndrome or exogenous glucocorticoid use; acromegaly (growth hormone excess); nephrotic syndrome, where urinary protein loss may include SHBG; and exogenous androgen administration, including testosterone replacement therapy and anabolic steroid use.

SHBG and Polycystic Ovary Syndrome (PCOS)

The relationship between SHBG and PCOS deserves special attention because low SHBG is both a diagnostic clue and a pathophysiological driver of the condition. PCOS affects approximately 6-12% of reproductive-age women worldwide and is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology.

In PCOS, insulin resistance promotes excessive ovarian and adrenal androgen production while simultaneously suppressing hepatic SHBG synthesis. This creates a vicious cycle: low SHBG allows more free testosterone to circulate, which further suppresses SHBG production through androgen-mediated hepatic effects. The net result is a disproportionate increase in bioavailable androgens that drives clinical features such as hirsutism, acne, and alopecia.

Studies have shown that the combination of SHBG and testosterone measurements (expressed as the FAI) performs better than total testosterone alone for identifying women with androgen excess. Some research, however, has cautioned that the strong inverse correlation between SHBG and obesity means the FAI may sometimes reflect the degree of obesity more than androgen excess per se. Clinicians should therefore interpret FAI results in the context of BMI and insulin resistance markers.

SHBG and Male Hypogonadism

In men, SHBG measurements are particularly valuable when total testosterone levels are borderline or discordant with clinical symptoms. The Endocrine Society Clinical Practice Guidelines recommend measuring SHBG and calculating free testosterone when total testosterone levels are near the lower limit of normal (approximately 8-12 nmol/L or 230-350 ng/dL) or when conditions known to alter SHBG are present.

Late-onset hypogonadism (also known as age-related testosterone deficiency) is characterized by gradually declining testosterone levels accompanied by rising SHBG. This combination results in a greater decrease in free and bioavailable testosterone than total testosterone alone would suggest. Men with elevated SHBG may have total testosterone values within the normal range but clinically significant free testosterone deficiency, presenting with symptoms such as decreased libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, mood changes, and decreased bone mineral density.

Conversely, men with obesity-related low SHBG may have low total testosterone but relatively preserved free testosterone levels. In these cases, the measured total testosterone may overestimate the degree of androgen deficiency. Weight loss in obese men has been shown to increase both SHBG and total testosterone while having variable effects on free testosterone, underscoring the importance of measuring multiple parameters rather than relying on any single value.

SHBG and Cardiovascular Risk

An expanding body of epidemiological evidence links SHBG levels to cardiovascular disease risk, though the relationship is complex and sex-specific. Multiple large population studies have demonstrated that low SHBG is independently associated with increased cardiovascular risk, insulin resistance, metabolic syndrome, and type 2 diabetes in both men and women.

In the Framingham Heart Study and other cohort studies, low SHBG predicted the development of metabolic syndrome and type 2 diabetes independently of BMI, fasting glucose, and other traditional risk factors. Some researchers have proposed that SHBG may have direct biological effects beyond its hormone transport function, potentially interacting with cell membrane receptors to influence intracellular signaling pathways involved in glucose and lipid metabolism.

Interestingly, the relationship between SHBG and cardiovascular outcomes shows age-dependent patterns. In population-based studies, older men with higher SHBG levels had increased cardiovascular risk in some analyses, possibly because very high SHBG results in low bioavailable testosterone, which itself has been associated with adverse cardiovascular outcomes. This U-shaped or context-dependent relationship highlights the importance of interpreting SHBG within the broader hormonal and metabolic profile rather than in isolation.

SHBG and Liver Function

Because SHBG is synthesized primarily in the liver, its serum concentration is sensitive to changes in hepatic function. SHBG has been proposed as a biomarker for liver health, with particular relevance to non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASLD).

Studies have consistently shown that low SHBG levels are associated with hepatic steatosis (fatty liver), elevated liver enzymes, and increased liver fat content as measured by imaging studies. The mechanism involves insulin resistance: hyperinsulinemia, a hallmark of NAFLD, directly inhibits hepatic SHBG gene transcription via effects on hepatocyte nuclear factor 4-alpha (HNF-4alpha), a key transcription factor for SHBG production.

In chronic liver disease progressing to cirrhosis, the pattern shifts. Cirrhotic patients often have elevated SHBG levels because impaired hepatic clearance of estrogens leads to hyperestrogenism, which stimulates SHBG production. This paradoxical increase in late-stage liver disease can complicate the interpretation of hormone levels in patients with advanced hepatic dysfunction.

How to Interpret Your SHBG Results

Interpreting SHBG results requires consideration of the clinical context, including the patient’s sex, age, BMI, medications, and concurrent medical conditions. SHBG should never be interpreted in isolation but rather as part of a comprehensive hormonal and metabolic assessment.

For men, an SHBG level above 50-60 nmol/L combined with symptoms of androgen deficiency warrants calculation of free testosterone using the Vermeulen equation. If calculated free testosterone falls below 0.225 nmol/L (approximately 6.5 ng/dL), this may support a diagnosis of hypogonadism even if total testosterone is within the normal range. Conversely, if SHBG is low (below 15-20 nmol/L), the clinician should investigate for insulin resistance, metabolic syndrome, hypothyroidism, or exogenous androgen use.

For women, an SHBG level below 25-30 nmol/L should prompt evaluation for PCOS, insulin resistance, and metabolic syndrome. The FAI should be calculated, and values above 5 in premenopausal women are suggestive of androgen excess. However, context matters: a woman on oral contraceptive pills will typically have SHBG levels of 100-200 nmol/L or higher, while a woman with PCOS and insulin resistance may have levels below 20 nmol/L.

Natural Ways to Modify SHBG Levels

While SHBG levels are influenced by many factors, several lifestyle modifications have been shown to alter SHBG concentrations. These interventions may be relevant for individuals whose SHBG levels are contributing to hormonal imbalances.

To increase low SHBG, evidence-based strategies include weight loss (particularly reduction of visceral fat), improving insulin sensitivity through regular aerobic and resistance exercise, reducing simple carbohydrate and refined sugar intake, increasing dietary fiber consumption, moderate coffee intake (which has been associated with higher SHBG in some studies), and ensuring adequate thyroid function. Caloric restriction and intermittent fasting have also been associated with SHBG increases, though extreme caloric deficit should be avoided.

To decrease elevated SHBG, options are more limited and generally require medical intervention. However, ensuring adequate caloric intake (avoiding prolonged caloric restriction), treating underlying hyperthyroidism, reviewing medications that may be increasing SHBG (such as oral estrogens or anticonvulsants), and optimizing body composition may help. In cases where high SHBG is causing clinically significant androgen deficiency in men, testosterone replacement therapy may be considered under medical supervision.

Limitations and Considerations

Several important limitations should be considered when using SHBG-based calculations for clinical decision-making. First, SHBG assays are not fully standardized across all laboratory platforms, meaning that values from different laboratories may not be directly comparable. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has been working toward standardization, but variations remain.

Second, the Vermeulen equation assumes normal levels of other steroid hormones (particularly estradiol and DHT) that also bind to SHBG. In conditions where these hormones are significantly elevated (such as pregnancy, exogenous estrogen therapy, or 5-alpha-reductase inhibitor use), the calculated free testosterone may not accurately reflect true free testosterone levels.

Third, the association constants used in the Vermeulen equation (Kt for SHBG-testosterone binding and Ka for albumin-testosterone binding) were derived from in vitro studies and may not perfectly reflect in vivo binding dynamics across all populations and conditions. Some researchers have proposed modified constants for specific clinical scenarios.

Fourth, genetic polymorphisms in the SHBG gene can affect both the quantity and binding affinity of SHBG, which may influence the accuracy of calculated free testosterone values. Population-specific differences in SHBG genetics have been documented, which is relevant when applying reference ranges derived from one population to individuals from another.

SHBG Testing: When and Why

SHBG testing is not part of routine health screening but is ordered when specific clinical scenarios warrant a more detailed assessment of hormonal status. Common indications for SHBG testing include evaluation of suspected hypogonadism in men when total testosterone is borderline; investigation of hyperandrogenism in women, particularly when PCOS is suspected; assessment of hormone levels in patients with conditions known to alter SHBG (obesity, thyroid disease, liver disease); monitoring during testosterone replacement therapy; unexplained infertility in either sex; and evaluation of pubertal disorders in adolescents.

The test requires a simple blood draw, typically performed in the morning when testosterone levels are at their physiological peak (following the normal diurnal pattern). Fasting is not strictly required for SHBG measurement but may be requested if concurrent insulin or glucose testing is planned. Results are usually available within one to three business days.

Validation Across Diverse Populations

SHBG reference ranges and their clinical correlations have been studied across diverse populations worldwide. Research has demonstrated that SHBG levels vary with ethnicity, with some studies showing lower mean SHBG levels in populations with higher rates of insulin resistance and metabolic syndrome. For example, studies from South Asia and the Middle East have reported lower mean SHBG levels compared to European populations, which may partly reflect differences in metabolic risk factor prevalence.

The Vermeulen equation for calculating free testosterone has been validated in North American, European, and Asian populations. However, clinicians should be aware that the original association constants were derived from studies in predominantly European populations, and some investigators have suggested that population-specific adjustments may improve accuracy in certain ethnic groups. Alternative calculators and equations exist, including the Sodergard equation, the Nanjee-Wheeler equation, and the Ly-Handelsman equation, each using slightly different association constants and yielding somewhat different calculated free testosterone values.

Regional Variations and Alternative Calculators

While the Vermeulen equation remains the most widely cited method for calculating free testosterone, several alternative approaches are used in clinical practice. The ISSAM (International Society for the Study of Aging Male) calculator, hosted by the University Hospital of Ghent, Belgium, is the most commonly referenced online implementation of the Vermeulen equation. The UK’s NICE guidelines reference calculated free testosterone in the evaluation of male hypogonadism, while the European Association of Urology guidelines recommend free testosterone calculation when total testosterone is between 8 and 12 nmol/L.

In clinical practice, the Free Androgen Index remains widely used in many countries, particularly for screening women for androgen excess. The Endocrine Society has endorsed its use in women but cautioned against its application in men, where it correlates poorly with directly measured free testosterone (r-squared values of only 0.21-0.46 in validation studies). The UK’s QRISK cardiovascular risk calculator incorporates SHBG as one of many variables, reflecting the growing recognition of SHBG’s role in metabolic risk assessment.

Frequently Asked Questions

Conclusion

Sex Hormone Binding Globulin occupies a central position in reproductive endocrinology and metabolic medicine. Far from being a passive transport protein, SHBG actively regulates the bioavailability of sex hormones and serves as a sensitive barometer of metabolic health, insulin sensitivity, and liver function. Understanding SHBG levels and their impact on free and bioavailable testosterone is essential for the accurate diagnosis and management of conditions ranging from hypogonadism and PCOS to metabolic syndrome and cardiovascular disease.

The SHBG calculator provided on this page equips users with the tools to compute the Free Androgen Index, estimated free testosterone (Vermeulen method), and bioavailable testosterone from standard laboratory measurements. By integrating these derived values with clinical context, age- and sex-specific reference ranges, and an understanding of the factors that influence SHBG, clinicians and patients can gain a more complete and accurate picture of hormonal status than total testosterone measurement alone provides. As always, these calculations should complement rather than replace professional medical evaluation and clinical judgment.